UBS Group’s Galectin Therapeutics Inc. - Warrants GALTW Stock Holding History

UBS Group’s Portfolio GALTW Stock Details GALTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-2,112	Closed	–	–	8412
2016 Q4	$0	Sell	2,112 -800	-27%	-$67	﹤0.01%	8433
2016 Q3	$0	Buy	+2,912	New	+$1.03K	﹤0.01%	8359

UBS Group's GALTW Position: Q1 2017 in Review

UBS Group sold out of Galectin Therapeutics Inc. - Warrants (GALTW) in Q1 2017, closing a stake of 2,112 shares.

UBS Group first reported a position in GALTW in Q3 2016 and held it in 2 quarters. The position peaked at $0 in Q4 2016. 0 funds tracked by Wall St. Rank hold GALTW as of Q1 2017.

UBS Group reported no remaining Galectin Therapeutics Inc. - Warrants position as of Q1 2017 after selling out during the quarter.
UBS Group sold 2,112 Galectin Therapeutics Inc. - Warrants shares in Q1 2017.
UBS Group first reported a position in Galectin Therapeutics Inc. - Warrants in Q3 2016 and held it in 2 quarters.
UBS Group's Galectin Therapeutics Inc. - Warrants position peaked at $0 in Q4 2016.
0 funds tracked by Wall St. Rank held Galectin Therapeutics Inc. - Warrants as of Q1 2017.

Based on UBS Group's 13F filing for Q1 2017, filed 12 May 2017.